Form 4 for ANAB ANAPTYSBIO, INC
Accepted 2021-12-22 00:00:00 ET · period of report 2021-12-20 · accession 0001209191-21-070986 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-22 | 2021-12-20 | ANAB | Suria Hamza | Pres, CEO, Dir | S - Sale+OE | $35.57 | -36.6K | 93.3K | -28% | -$1.30M |
| D | 2021-12-22 | 2021-12-20 | ANAB | Suria Hamza | Pres, CEO, Dir | M - OptEx | $1.12 | +36.6K | 105.2K | +53% | +$41.0K |
| D | 2021-12-22 | 2021-12-20 | ANAB | Suria Hamza | Pres, CEO, Dir | M - OptEx | $0.00 | -36.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-20 | S | D | 5,522 | $36.40 | 68,600 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.26 to $36.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 2 | Common | Common Stock | 2021-12-20 | S | D | 19,208 | $35.75 | 74,122 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 3 | Common | Common Stock | 2021-12-20 | M | A | 36,645 | $1.12 | 105,245 | D | — | — | |
| 4 | Common | Common Stock | 2021-12-20 | S | D | 11,915 | $34.89 | 93,330 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2021-12-20 | M | D | 36,645 | $0.00 | 0 | D | $1.12 · — to 2022-01-31 | 36,645 Common Stock | (F6) In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly. (F5) The stock option grant was issued on February 1, 2012, is fully vested and exercisable until its expiration date of January 31, 2022. |